MLM Ranks

Medifast Q1 2026 Results Amid Strategic Shift

Medifast Reports Q1 2026 Financial Results Amid Strategic Transformation

Medifast, Inc. (NYSE: MED) released its first quarter 2026 financial results today. The metabolic health and wellness company is focused on its science-backed, coach-guided model while navigating industry challenges.

Q1 2026 Key Highlights

  • Revenue: $76.0 million

  • Revenue per Active Earning Coach: $5,432 (up 19.2%)

  • Active Earning Coaches: 14,000

  • Net Loss: $2.1 million ($0.19 per diluted share)

  • Cash & Investments: $168.9 million (zero debt)

Medifast achieved its second consecutive quarter of year-over-year growth in coach productivity.

Professional headshot of Dan Chard, the CEO of Medifast, wearing a suit and tie against a grey background.

Financial Performance Overview

Revenue declined 34.3% to $76.0 million from $115.7 million in Q1 2025. The decrease was primarily due to a 44.9% drop in active earning coaches to 14,000, influenced by broader market challenges including the rapid adoption of GLP-1 weight-loss medications.

However, revenue per active earning coach rose strongly by 19.2% to $5,432, reflecting improved coach alignment, focus on productive coaches, and better network efficiency.

Gross profit was $51.8 million with a gross margin of 68.1%. SG&A expenses fell 35.6% to $55.1 million, helped by lower coach compensation, reduced marketing spend, and a $2.2 million one-time gain from the sale of the Maryland distribution center.

The company reported a net loss of $2.1 million for the quarter.

CEO Statement

“We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy,” said Dan Chard, CEO of Medifast.

“Coach productivity growth, strong leadership advancement, and high field engagement are positive leading indicators. Supported by our differentiated science and disciplined cost management, we are positioned to deliver improved performance through the rest of 2026 and achieve sustainable long-term growth.”

Strong Balance Sheet

Medifast ended the quarter with $168.9 million in cash, cash equivalents, and investment securities and no debt. Working capital stood at $160.4 million, demonstrating continued financial strength.

2026 Outlook

  • Q2 2026 Revenue: $60 million – $80 million

  • Q2 2026 Loss per Share: $0.50 – $1.00

  • Full Year 2026 Revenue: $270 million – $300 million

  • Full Year 2026 Loss per Share: $1.55 – $2.75

The company expects active earning coaches to continue declining in 2026 as it prioritizes quality and metabolic health focus.

About Medifast

Medifast (NYSE: MED) is a leading metabolic health and wellness company offering a science-backed, coach-guided lifestyle system. Its holistic approach combines personalized plans, clinically developed products, and habit-building support through a network of independent coaches.

With over 40 years of clinical heritage, Medifast is advancing innovations like Metabolic Synchronization® to help reverse metabolic dysfunction, reduce visceral fat, preserve muscle, and support lifelong healthy transformation.

RELATED ARTICLES

Reviews:

There are no reviews yet. Be the first one to write one.

Leave Your Review Here:

MLM Ranks YouTube channel disclaimer outlining general info, no financial advice, earnings disclaimer, and copyright notice.